	<small>Title</small> 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	<small>Doc id</small> MA-43263
--	--	--

Statistical Analysis Plan

Clinical Trial Number: 43QM1901

Effective date: 2021-02-05 13:17

Effective

Version: 1.0


	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Table of Contents

1	Study Information	4
1.1	Background	4
1.1.1	Study design	4
1.1.2	Number of subjects and randomization	4
1.2	Study Objectives	4
1.2.1	Primary efficacy objective	4
1.2.2	Secondary efficacy objectives	4
	CCI	
1.2.4	Safety objective	5
1.3	Efficacy assessment	5
1.3.1	Investigator 4-point Photographic Scale of Lateral Canthal Line Severity: Investigator Live Assessment (LCL-ILA)	5
1.3.2	Subject 4-point Photographic Scale of Lateral Canthal Line Severity: Subject Live Assessment (LCL-SLA)	6
	CCI	
1.4	Efficacy endpoints	9
1.4.1	Primary efficacy endpoint	9
1.4.2	Secondary efficacy endpoints	9
	CCI	
1.5	Safety assessments and endpoints	11
1.5.1	Adverse events	12
1.5.2	Laboratory safety tests	12
1.5.3	Focused physical examination	12
1.5.4	Vital signs	12
1.5.5	Neutralizing antibody testing	12
1.5.6	Electrocardiogram (ECG)	12
2	Statistical Methods	14
2.1	General methods	14
2.1.1	Visit windows	14
2.1.2	Pooling of Centers	14
2.2	Analysis Populations	15
2.3	Study subjects	15
2.3.1	Subject disposition	15
2.3.2	Protocol deviations	15
2.3.3	Demographic characteristics	16
2.3.4	Medical history and previous/concomitant medication (including drugs and medical and surgical procedures)	17
2.4	Efficacy analysis	19
2.4.1	Datasets analyzed	19
2.4.2	Handling of missing data	19
2.4.3	Primary analysis	19

2.4.3.1	Sensitivity analysis.....	20
2.4.3.2	Subgroup analysis	20
2.4.4	Secondary analysis	20

CCI

2.5	Safety analysis.....	22
2.5.1	Extent of exposure	22
2.5.2	Adverse events	22
2.5.2.1	Subgroup analysis	24
2.5.2.2	Assessment of local/remote toxin spread and hypersensitivity	24
2.5.3	Laboratory assessments.....	25
2.5.4	Neutralizing antibody testing.....	25
2.5.5	Physical examinations and vital signs.....	25
2.5.6	ECG.....	25
2.5.7	Urine pregnancy test	25
2.6	Interim Analysis.....	25
2.7	Determination of Sample Size	26


CCI

2.7.3	Sample size calculation	26
2.8	Changes in Analysis Planned in the Protocol	26

3	Reference List.....	27
4	Appendix A LCL-ILA Scales	28
5	Appendix B LCL-SLA Scales.....	30

CCI

9	Appendix F Schedule of Assessments.....	36
---	---	----

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

1 Study Information

This statistical analysis plan (SAP) describes the efficacy and safety summaries and analyses that will be performed for Clinical Trial Number (CTN) 43QM1901, *A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines (READY - 2)* and is based on the study protocol Version 4 dated 10JUN2020.

1.1 Background

1.1.1 Study design

This is a phase 3, multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of 60 units of QM1114-DP for the treatment of moderate to severe lateral canthal lines (LCL).

Each subject will receive a single treatment of QM1114-DP 60 units or placebo divided equally among 6 injection points (0.1 mL per injection point) in the LCL region. Following treatment at baseline, subjects will be monitored for safety and efficacy for 6 months.

1.1.2 Number of subjects and randomization

The study will screen approximately 330 male and female adults, 18 years of age and older, with moderate to severe bilaterally symmetrical LCL at maximum smile in up to 15 study sites in the US and Canada. Following the screening process, eligible subjects will be randomized at the baseline visit (Day 0) in a 3:1 ratio to QM1114-DP or placebo, stratified by site.

1.2 Study Objectives

The objective of the study is to evaluate the efficacy and safety of a single dose of 60 units of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.


1.2.1 Primary efficacy objective

The primary efficacy objective of the study as assessed using the endpoints outlined in [Section 1.4.1](#) is to evaluate a single dose of 60 units of QM1114-DP compared to placebo for the treatment of moderate to severe LCL using the Investigator 4-point Photographic Scale of Lateral Canthal Line Severity (LCL-ILA) (described in [Section 1.3.1](#)) and Subject 4-point Photographic Scale of Lateral Canthal Line Severity (LCL-SLA) (described in [Section 1.3.2](#)) at maximum smile.

1.2.2 Secondary efficacy objectives

The secondary efficacy objective of the study as assessed using the endpoints outlined in [Section 1.4.2](#) is to evaluate the efficacy of a single dose of 60 units of QM1114-DP compared to placebo for the treatment of moderate to severe LCL using the LCL-ILA.

CCI

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	---	---------------------------

Effective date: 2021-02-05 13:17

CCI

1.2.4 Safety objective

The safety objective of the study is to evaluate the safety of a single dose of 60 units of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.

1.3 Efficacy assessment

For all assessments, baseline will be defined as the observation that is closest to but prior to study injection on Day 0. Likewise, in general, change from baseline (Δ) will be calculated as the value at a given time point, X , minus the baseline value:

$$\Delta = X \text{ Value} - \text{Baseline (Day 0) Value}$$

1.3.1 Investigator 4-point Photographic Scale of Lateral Canthal Line Severity: Investigator Live Assessment (LCL-ILA)

The LCL-ILA is a 4-point validated scale for assessment of lateral canthal lines ([Appendix A](#)). The validated LCL-ILA, developed by Galderma, includes two grading systems: one for Investigator live assessments at maximum smile, CCI. The scale represents LCL severities from none (grade 0), mild (grade 1), moderate (grade 2), to severe (grade 3). Each grade is also depicted by an individual photograph and descriptive text.


The Investigators will use the LCL-ILA for direct, live comparison with the subject's face at CCI at maximum smile. Left and right LCL should be assessed separately at CCI maximum smile. The Investigator will perform the LCL-ILA at:

- Screening/Baseline (prior to treatment) visit(s)
- all post-treatment visits.

Multiple responder indicators will need to be created as follows:


- Primary endpoint LCL-ILA indicator: subjects that achieved a score of 0 or 1 in LCL severity, and had at least 2 grade improvement from baseline at maximum smile at Month 1, for both left and right LCL, will have the value '1'. This indicator will be used in combination with the primary endpoint LCL-SLA indicator to define the primary endpoint composite responder.
- Subjects who achieve a score of 0 or 1 in the LCL-ILA at maximum smile, for both left and right LCL, at each respective post-baseline visit will be considered an LCL-ILA at maximum smile responder for that visit

CCI

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17

CCI



1.3.2 Subject 4-point Photographic Scale of Lateral Canthal Line Severity: Subject Live Assessment (LCL-SLA)

Similar to the LCL-ILA, subjects will also assess their LCL severity using the LCL-SLA ([Appendix B](#)). The validated LCL-SLA, developed by Galderma, includes two grading systems: one for the subject's live assessments at maximum smile, CCI. The scale represents LCL severities from Level 0, Level 1, Level 2, to Level 3. Each grade is also depicted by an individual photograph and descriptive text.


This subject assessment will be done independently of the Investigator's assessment. Subjects will be asked to evaluate their LCL at maximum smile CCI (left and right side separately) at:

- Screening/Baseline (prior to treatment) visit(s)
- all post-treatment visits

Multiple responder indicators will need to be created as follows:

- Primary endpoint LCL-SLA indicator: subjects that achieved a score of 0 or 1 in LCL severity, and had at least 2 grade improvement from baseline at maximum smile at Month 1, for both left and right LCL, will have the value '1'. This indicator will be used in combination with the primary endpoint LCL-ILA indicator to define the primary endpoint composite responder.
- Subjects who achieve a score of 0 or 1 in the LCL-SLA at maximum smile, for both left and right LCL, at each respective post-baseline visit will be considered an LCL-SLA at maximum smile responder for that visit

CCI




Version: 1.0


Effective date: 2021-02-05 13:17

Effective

Version: 1.0

	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	--	--


CCI




Effective date: 2021-02-05 13:17


Effective

Version: 1.0


	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	--	--



CCI

	Title 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17



1.4 Efficacy endpoints

1.4.1 Primary efficacy endpoint


The primary efficacy endpoint is the composite responder rate at Month 1 using LCL-ILA and LCL-SLA at maximum smile.

A composite responder is defined as a subject who achieves a score of 0 or 1 in lateral canthal line severity, and at least 2 grades improvement from baseline on both the LCL-ILA and LCL-SLA scales, concurrently, at Month 1 for both left and right sides.


1.4.2 Secondary efficacy endpoints

Secondary endpoints include:

- (i) Percentage of subjects who achieve a score of 0 or 1 at the same visit for both left and right sides summarized for each post-treatment visit using the LCL-ILA at maximum smile



Version: 1.0

	<p><small>Title</small> 43QML901 Statistical Analysis Plan US - QM1114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	---	---


Effective date: 2021-02-05 13:17

CCI




Effective

Version: 1.0

	Title 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL	Doc id MA-43263
--	--	----------------------------------


Effective date: 2021-02-05 13:17

CCI



1.5 Safety assessments and endpoints

For details regarding the safety assessments, please refer to the Clinical Study Protocol (CSP) Section 7.2.

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

1.5.1 Adverse events

Adverse events (AEs) are to be monitored throughout the course of the study. All AEs reported will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, version in force at the time of database freeze) and classified by MedDRA preferred term (PT) and system organ class (SOC). AEs will be defined as treatment-emergent adverse events (TEAEs) if the AE had an onset time greater than or equal to the time of study treatment. The study period for the purpose of AE collection is defined as the period from the signing of a study specific informed consent to study exit.

A two-point scale ("Yes" or "No" response) will be used for the causality assessments. The Treating Investigator should be asked to indicate a response to each of the following questions in the electronic Case Report Form (eCRF):

- "Do you consider that there is a reasonable possibility that the event may have been caused by the study product?"
- "Do you consider that there is a reasonable possibility that the event may have been caused by the study product injection procedure?"

If either of these questions is answered with a 'Yes', the AE will be considered related.

AE endpoints include incidence and severity of TEAEs.

1.5.2 Laboratory safety tests

Hematology and blood chemistry laboratory tests will be performed at baseline (before treatment) and Month 6. Laboratory safety test endpoints include:

- Values collected at each visit
- Changes from baseline

1.5.3 Focused physical examination

Physical examination will be done at screening/baseline (before treatment), Day 7, Day 14, Month 1, and Month 6. Normal, abnormal and clinically significant findings will be assessed.

1.5.4 Vital signs

Vital signs will be assessed from baseline (before and after treatment), Day 7, Day 14, Month 1, and Month 6. Vital signs endpoints include:


- Values collected at each visit
- Changes from baseline

1.5.5 Neutralizing antibody testing

Blood samples will be taken for measurement of serum neutralizing antibody testing against QM1114-DP at baseline (before treatment), Month 1, and Month 6. Analysis of the blood samples include in vitro screening and confirmatory (if positive screening result) ELISA assays to test for the presence of binding antibodies, and in vivo mouse protection assay (MPA) to test for the presence of neutralizing antibodies. The MPA will only be conducted if the subject has a positive confirmatory result.

1.5.6 Electrocardiogram (ECG)

ECG recordings will be done at baseline (before treatment), Month 1, and Month 6. The following items will be measured:

	Title 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

- RR interval
- PR interval
- QRS interval
- QT interval
- Heart rate (HR)
- QTcB interval
- QTcF interval


During each visit where ECG is conducted, the ECG will be recorded in triplicates. In addition to the individual measurements, the above items will be aggregated into a mean value per visit (mean of all beats). ECG endpoints include:

- Aggregated values collected at each visit
- Changes from baseline
- QTcB and QTcF prolongation criteria
- Overall assessment (Normal, Abnormal Not Clinically Significant, Abnormal Clinically Significant) of the ECG

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

	Title 43QM1901 Statistical Analysis Plan US - QM114-DP - LCL	Doc id MA-43263
--	---	----------------------------------

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

2 Statistical Methods

2.1 General methods

All tables, listings, and figures will be programmed using SAS Version 9.4 or higher. Data collected in this study will be documented using summary tables and subject data listings created by using the SAS® system. Confidence intervals (CI) and p-values will be 2-sided and performed at a significance level of 5%, unless otherwise specified. Data for all subjects in the clinical database will be included in the data listings. Calculated (derived) variables will be listed as appropriate. Any changes from the SAP will be detailed in the clinical study report.

All efficacy, safety and baseline characteristics variables will be presented using descriptive statistics within each treatment group, and graphs as appropriate. Continuous variables will be summarized using descriptive statistics (number of observations, mean, standard deviation [SD], median, minimum, and maximum). Categorical variables will be presented in frequency tables with number and percentage of observations for each level. Missing counts for all variables will be presented for informational purposes only and will not be included in percentage calculations.

Study days will be calculated relative to the injection of study drug. Day 0 will be the day of study drug administration. Baseline will be the last assessment prior to the injection of study drug unless otherwise indicated. The Screening Visit 1 (Day -14 to Day 0) will be considered the visit prior to injection of study drug. Because the Screening visit and Baseline visit (Day 0) may be performed on the same day, the Screening visit can also be Day 0.

Adverse events, cosmetic/aesthetic procedures and implant history events, medical history events, and concomitant treatments/procedures will be coded using MedDRA, Version 23.0. Prior/concomitant medications and procedural anesthetics will be coded using the World Health Organization (WHO) Drug Dictionary Global, 1 Sep 2019 B3 or higher.

In general, efficacy, safety, **CCI** analyses will be performed and summarized by treatment group (QM114-DP, placebo), unless otherwise stated.


2.1.1 Visit windows

Study visits are expected to occur according to the protocol schedule in [Appendix F](#). All data will be tabulated per the evaluation visit as recorded on the eCRF even if the assessment is outside of the visit window. In data listings, the relative study day (in relation to date of study drug administration) of all dates will be presented. There will not be any windowing for unscheduled visits in the analysis, and unscheduled visits will not be included in any analyses. Unscheduled visits, if any, will be presented in listings only.

2.1.2 Pooling of Centers

As this is a multi-center study, it is possible that some sites may only enroll a small number of subjects. Since this study plans to conduct some site-level analyses, pooling of sites may need to be considered for reliable and accurate results. If any site enrolls less than 5 subjects, then sites will be pooled by the following geographic regions:

- US sites
 - East
 - North
 - South

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

- West
- Canadian sites
 - If only one site exists in this country, then its region will be pooled with the respective US region above (i.e. Canada – East will be pooled with US – East); otherwise sites will be pooled into the following geographic regions:
 - East
 - North
 - South
 - West

This region-level site grouping will then be used for all site-level analyses. This will be done prior to unblinding.

2.2 Analysis Populations

The statistical analyses will be performed based on the following four subject populations:

- Modified Intent-to-Treat efficacy population – The modified Intention-to-treat (mITT) population includes all subjects who are randomized and dispensed the investigational product, and will be analyzed according to the randomization scheme; subjects with a photographic and categorical scale Month 1 assessment via a remote visit will be excluded from the mITT.
- Intention-to-treat efficacy population - The Intention-to-treat (ITT) population includes all subjects who are randomized and dispensed the investigational product, and will be analyzed according to the randomization scheme.
- Per-protocol efficacy population - The Per-protocol (PP) population is a subset of the mITT subjects who have no protocol deviations that are considered to have a substantial impact on the primary efficacy outcome.
- Safety population - The safety population includes all subjects who were administered the study product and will be analyzed according to as-treated principle.

2.3 Study subjects


2.3.1 Subject disposition

Subject disposition will be presented by treatment group and overall. The number of subjects in each study population (i.e. mITT, ITT, PP and Safety) will be summarized. Study population variables will also be presented in a data listing. Study completion, as well as early discontinuation, will be described for all subjects as well as by visit and by center.

Reasons for early discontinuation will be summarized and listed. All withdrawn subjects will be listed individually, including at least subject number, date and reason for withdrawal, and last visit performed, along with the relevant comments recorded on the eCRF (i.e., the Exit Form).

2.3.2 Protocol deviations

A protocol deviation occurs when a subject deviates from the protocol procedures. Depending on the seriousness of the deviation, the subject might be excluded from the PP analysis. Since PP will be used for the primary analysis at Month 1 only, the focus will be on deviations occurring before and on Month 1 visit day, as they might compromise the primary endpoint.

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

For this study, the protocol deviations that will exclude subjects from PP are identified in (but not limited to) [Table 2](#) below.

Table 2. Protocol deviations

Deviation
Any subject that conducts their Month 1 visit out of window by greater than 14 days or earlier than 7 days
Any subject not treated according to the assigned treatment
Any subject that does not complete the LCL-ILA at maximum smile at the primary endpoint visit (Month 1)
Any subject that does not complete the LCL-SLA at maximum smile at the primary endpoint visit (Month 1)
Any subject that does not have an available screening or baseline LCL-ILA at maximum smile assessment
Any subject that does not have an available screening or baseline LCL-SLA at maximum smile assessment
Any subject that does not have grade 2 or 3 at maximum smile on the LCL-ILA at baseline
Any subject that do not have grade 2 or 3 at maximum smile on the LCL-SLA at baseline
Any subject with prohibited concomitant treatments/procedures prior to Month 1 visit considered to have a substantial impact on the primary efficacy outcome.
Any subject with a prohibited medical history, unstable medical history condition, or medical history condition that worsens prior to Month 1 visit considered to have a substantial impact on the primary efficacy outcome

Before unblinding the subject data, and as a part of preparations for the database lock, the study team will review all protocol deviations. All protocol deviations will be presented in a data listing.

Handling of Protocol Deviations During COVID-19

Due to the public health emergency related to the COVID-19 pandemic during 2020, steps have been taken to ensure patient and practitioner safety in alignment with FDA Guidance dated May 11, 2020 (Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency). Most notably, in partnership with clinical sites and the Institutional Review Board (IRB), optional remote assessment procedures for efficacy and safety endpoints have been implemented to ensure safety and respect localized and elective restrictions.


Protocol deviations will be presented descriptively, overall and by treatment group. The total number of deviations, the type of protocol deviation, and if the deviation was reportable to the IRB will be summarized. These summaries will be stratified by relatedness to COVID-19 (related, not related). The above summary of protocol deviations will be repeated by site as well.

A listing of all protocol deviations reported throughout the study, including their relatedness to COVID-19, will be provided.

2.3.3 Demographic characteristics

Demographic assessments for this study include:

- Age (years)
- Height (in)
- Weight (lbs.)

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

- BMI (kg/m²)
- Gender (Male, Female)
- Ethnicity (Hispanic or Latino, Not Hispanic or Latino)
- Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other)
- FST score (I, II, III, IV, V, VI)
- Prior use of botulinum toxin (Naive, Non-Naive)

Subject demographic data will be summarized for the ITT population by treatment group and overall. Age, height, weight, and BMI, will be analyzed as continuous variables. Gender, race, ethnicity, Fitzpatrick skin type, and prior botulinum toxin use status will be analyzed as categorical variables.

Demographics and baseline characteristics will be presented by subject in a data listing.

2.3.4 Medical history and previous/concomitant medication (including drugs and medical and surgical procedures)

All summaries will be done by treatment group based on the ITT population. History of relevant or clinically significant surgical events and medical conditions, including any prior cosmetic/aesthetic procedures or implants, will be collected. Medical History will be coded according to MedDRA; the version used will be noted as a footnote in the tables and listings.


The number and percentage of subjects reporting medical history will be summarized by system organ class (SOC) and preferred term (PT). System organ class and PTs will be presented in descending frequency first based on the QM1114-DP group, and then alphabetically if there are ties. Each subject will contribute at most one count per summarization category. In other words, if a subject has more than one medical history event with same PT, the subject will be counted only once for that PT. Similarly, if a subject has more than one medical history event for a SOC, the subject will be counted only once in that SOC.

Cosmetic/aesthetic procedures and/or implant history will also be presented and will follow the same methods specified above.

Medical history, and prior cosmetic/aesthetic procedures or implants will be provided in the subject data listing. Medical history will be further presented in a separate listing by past and ongoing LCL medical history.

Concomitant medications for this study are defined as any ongoing medications with a start date prior to the date of injection, any changes to existing medications (such as dose or formulation) during the course of the study, or any new medications received by the subject since the date of injection. Prior medications are medications with stop dates prior to study treatment and used within 4 weeks preceding screening visit. Medications will be coded using the World Health Organization (WHO) Drug Dictionary; concomitant procedures will be coded according to MedDRA. The versions used for the coding will be noted as a footnote in the tables and listings.

The number and percentage of subjects who receive prior and concomitant medications will be summarized by the WHO Drug Dictionary Anatomical Therapeutic Chemical 3rd level (ATC-3) and the preferred name. If the 3rd level term is not available, the next available level (e.g., ATC-2)

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

will be used. In addition, the number and percentage of subjects reporting a concomitant medication/therapy will be summarized by reason (medical history, adverse event, concomitant procedure, contraception, or other). Therapies and procedures that started due to an AE will be summarized separately from those who did not start due to an AE.

ATC-3 and preferred name will be presented in descending frequency first based on the QM1114-DP group, and then alphabetically if there are ties. Each subject will contribute at most one count per summarization category. In other words, if a subject has more than one medication with same preferred name, the subject will be counted only once for that preferred name. Similarly, if a subject has more than one medication for an ATC-3 level, the subject will be counted only once in that ATC-3 level and preferred name. Concomitant procedures will also be presented and will follow the same methods specified for medical history.


Prior and concomitant medications/procedures will be presented by subject in a data listing.

Handling of Missing/Partial Dates

While every effort will be made to obtain full, complete information on every reported medication, the following imputation rules will be followed for any respective missing medication data:

For the purpose of determining whether a medication is considered prior or concomitant, the following date imputation rules will be used. Dates will be presented as collected in the listings.

- Start Date
 - If the start date is completely missing, it will be assumed that the medication started on the study treatment date.
 - If the start date is missing the day, the first of the month will be used (i.e. UNK-JAN-2019 becomes 01-JAN-2019), provided the imputed date is on or after the subject's study treatment date; otherwise, the day of study treatment will be used.
 - If the start date is missing the month, the month of 'June' will be used (i.e. 01-UNK-2019 becomes 01-JUN-2019), provided the imputed date is on or after the subject's study treatment date; otherwise, the subsequent month after study treatment will be used.
 - If the start date is missing the year, the year of study treatment will be used (i.e. 01-JAN-UNK becomes 01-JAN-2019), provided the imputed date is on or after the subject's study treatment date; otherwise, the subsequent year after treatment will be used.
- End Date
 - If the end date is completely missing, it will be assumed that the medication is still ongoing and will not be imputed.
 - If the end date is missing the day, the last day of the month will be used (i.e. UNK-JAN-2019 becomes 31-JAN-2019).
 - If the end date is missing the month, the subsequent month after the start date will be used.
 - If the end date is missing the year, the year of study treatment will be used (i.e. 01-JAN-UNK becomes 01-JAN-2019), provided the imputed date is after the start date; otherwise, the subsequent year after start date will be used.

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	---	---------------------------

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

2.4 Efficacy analysis

2.4.1 Datasets analyzed

The primary efficacy analysis will be analyzed based on the mITT population. All secondary efficacy **CCI** variables will be analyzed based on the ITT population, unless otherwise specified below.

2.4.2 Handling of missing data

In general, the number of subjects with missing values will be summarized and reported as appropriate in all outputs. The primary analysis will be performed using multiple imputation (MI) as the primary imputation method and repeated using baseline observation carried forward (BOCF) as a sensitivity analysis for missing values. With the BOCF imputation method, if a subject is missing their Month 1 LCL-ILA score or Month 1 LCL-SLA score, their LCL-ILA/LCL-SLA score at baseline will be used, respectively.

The imputation using MI will assume the Missing Completely at Random (MCAR) missing data assumption. Regardless of the actual pattern of missing data, the Markov Chain Monte Carlo (MCMC) method of the MI procedure from the SAS® system will first be used to create a monotonic pattern of missing data. Then, a second MI procedure will be used to generate five sets of data with missing values imputed from observed data. Linear regressions will be employed to model the missing left LCL-ILA, right LCL-ILA, left LCL-SLA, and right LCL-SLA scores separately, with the following covariates included in each imputation model: treatment group and non-missing LCL-ILA or LCL-SLA data, respectively, from earlier timepoints (baseline, Day 7, and Day 14). The imputed datasets will be used to create the composite responder variable, which will then be analyzed using the methodology described for the primary analysis of responder rates at Month 1 ([Section 2.4.3](#)). The results from the analysis of the multiple imputed datasets will be combined by the MIANALYZE procedure of the SAS® system. The seed number to be used will be the number 110198.

The secondary efficacy analysis (described in [Section 2.4.4](#)) will be performed using the Observed Cases (OC), that is, no imputation will be done. **CCI**

2.4.3 Primary analysis

The primary efficacy endpoint will be the composite responder rate based on the LCL-ILA and LCL-SLA of lateral canthal line severity at maximum smile at Month 1 (described in [Section 1.3.1](#) and [Section 1.3.2](#), respectively). To evaluate the effectiveness of QM1114-DP versus placebo in the treatment of moderate to severe LCL, the responder rates of the QM1114-DP and placebo will be compared using the Cochran-Mantel-Haenszel (CMH) test, stratified by site, at the 5% significance level (2-sided).

The null hypothesis of no relationship between treatment and responder rate (i.e. the responder rates are the same in both groups) will be tested against the alternative hypothesis that there is a relationship between treatment and responder rate (i.e. the responder rates are different in the two groups). For a significant result, the two-sided p-value of the comparison of the composite LCL-ILA/LCL-SLA responder rates between the QM1114-DP treated and placebo treated subjects at

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Month 1 using the CMH test needs to be smaller than 0.05. The Breslow-Day test will be used to assess the homogeneity of the odds ratios across all sites.

The estimates of the composite LCL-ILA/LCL-SLA responder rates in each treatment group will be presented as well as the difference in responder rates (QM1114-DP responder rate – placebo responder rate). Corresponding 95% CI for the treatment group composite LCL-ILA/LCL-SLA responder rates and the difference in responder rates along with the p-value for the difference will also be presented. The normal approximation (Wald) method will be used to calculate both the 95% CI for the individual treatment group composite LCL-ILA/LCL-SLA responder rates and the 95% CI for the difference in responder rates. The above responder rates will be presented in figures by visit and treatment group.

2.4.3.1 Sensitivity analysis

To evaluate the impact of missing data on the primary endpoint, sensitivity analyses will be performed. The primary analysis specified in [Section 2.4.3](#) will be repeated using the BOCF method (detailed in [Section 2.4.2](#)), and also using the ITT OC.

In addition, a sensitivity analysis of the primary efficacy endpoint will be performed based on the PP population, and also on the Safety population to account for potential errors in randomization. The analysis method described above in [Section 2.4.3](#) will be repeated but using the PP population and Safety population.

2.4.3.2 Subgroup analysis


Additionally, to evaluate the consistency of the results of the primary analysis across different subgroups of interest, the primary analysis specified above ([Section 2.4.3](#)) will be repeated, stratifying for each of the following subgroups specified below:

- Age (less than 65 years old, 65+ years old)
- Gender (Male, Female; if enough males are recruited)
- Baseline Severity score of the LCL-ILA at maximum smile (Grade 2 (Moderate), Grade 3 (Severe), using the worst value from the right and left sides).
- Prior botulinum toxin use (Yes, No)
- Fitzpatrick skin type (I-III, IV-VI)
- Site
- Type of Month 1 visit (Onsite, Remote)

For each subgroup, the responder rates, difference in responder rates between the treatment groups, and the corresponding 95% CI will be presented. The Breslow-Day test will be used to assess the homogeneity of the odds ratios across all the subjects within each subgroup. The subgroup analysis for type of Month 1 visit will be performed based on the ITT population.

2.4.4 Secondary analysis

To evaluate the effectiveness of QM1114-DP versus placebo in the treatment of moderate to severe LCL, the proportion of subjects who achieve 0 or 1 on the LCL-ILA at maximum smile at Month 1 and at all the rest of the post-treatment visits will be compared using the CMH test, stratified by site. To control the type I error rate, the fixed sequence testing procedure will be used, which requires no adjustment to the level of significance. However, the comparisons must be made in a pre-specified order following the procedure outlined below:

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

1. Primary analysis must be done first, prior to any other analysis

Secondary analyses:


2. Month 1 responder rate
3. Day 14 responder rate
4. Month 2 responder rate
5. Month 3 responder rate
6. Month 4 responder rate
7. Month 5 responder rate
8. Month 6 responder rate
9. Day 7 responder rate


If one of the tests in the sequence is not significant ($p > 0.05$), no confirmatory claims can be made based on tests following (and including) that one.

The secondary analysis in the sequence will be based on the ITT population with the remote visit assessments excluded. A sensitivity analysis will be conducted using the ITT population including the remote visit assessments.

Results will include estimates of the percentages, difference in percentages, 95% CIs, and CMH p-value as well as a graph showing the percentages for the two treatment groups over time. For consistency across strata, the Breslow-Day test will be used.

CCI




	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17

Effective

CCI



2.5 Safety analysis

All safety data will be summarized descriptively based on the safety population. All of the safety analyses will be done using OC. If deemed necessary, any analyses may be repeated using OC, BOCF, or MI as appropriate.


2.5.1 Extent of exposure

There will only be limited exposure to QM1114-DP since it is injected only once according to treatment group assignment. The number of subjects receiving a single dose of QM1114-DP and placebo, respectively, will be presented.

2.5.2 Adverse events

All AE data will be summarized by treatment group. Missing dates will be imputed as described below. AEs will be summarized by SOC and PT. AEs occurring before treatment will be presented in listings only. The MedDRA version used for the coding will be noted as a footnote in the tables and listings.

Version: 1.0

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17

A summary of all AEs will be provided, which will include:

- number (%) of subjects who did not have an AE
- number (%) of subjects with at least one TEAE and number of events
- number (%) of subjects with at least one TEAE related to study product or injection procedure
- number (%) of subjects with at least one TEAE not related to study product or injection procedure
- number (%) of subjects with at least one TEAE leading to discontinuation
- number (%) of subjects with at least one serious TEAE.

Summaries of TEAEs (including the total number of events, number and percentage of subjects) will be displayed by treatment group according to the following:


- All TEAEs by SOC and PT
- Treatment emergent SAE by SOC, PT, maximum intensity (mild, moderate, severe), and causality
- Related TEAEs by SOC and PT, and maximum intensity (mild, moderate, severe)
- Unrelated TEAEs by SOC and PT, and maximum intensity (mild, moderate, severe)
- TEAEs leading to discontinuation by SOC and PT, and maximum intensity (mild, moderate, severe)
- TEAEs by SOC, PT, and action taken (none, medical treatment, non-pharmacological treatment, subject withdrawn)

For the subject level analyses, the number and percentage of subjects who experienced at least one of the events listed above will be summarized overall and for each SOC and each PT. System organ class and PTs will be presented in descending frequency first (by QM1114-DP group), and then alphabetically if there are ties. Each subject will contribute at most one count per summarization category. In other words, if a subject has more than one TEAE with same PT, the subject will be counted only once for that PT. Similarly, if a subject has more than one TEAE for a SOC, the subject will be counted only once in that SOC and PT. For the event level analyses, the counts of each respective event will be presented. In general, percentages will be calculated using the number of subjects in the safety population for the denominator. For the subgroup analyses (described in [Section 2.5.2.1](#)), percentages will be calculated using the number of subjects in the safety population for each respective sub-category as the denominator.

For the “action taken” summary specifically, subjects will be only counted in 'None' category if no other action was taken. The onset/duration summaries will be presented at the event level (i.e. will include multiple AEs within the same SOC and PT). Number of days to onset and duration of event will be summarized by SOC and PT, using mean, SD, minimum, maximum, and median statistics. Time to onset will be calculated as the first day with the AE *minus* the Day 0. Duration will be calculated as the last day with the AE *minus* the first day with the AE *plus* one. The text below lists the imputation rules for partial/completely missing dates. Missing stop date will not be imputed and therefore no duration will be calculated in these cases. Instead, the number of AEs that were ongoing at the end of the study will be given.

Handling of Missing/Partial Dates

While every effort will be made to obtain full, complete information on every reported AE, the following imputation rules will be followed for any respective missing AE data:

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

For the purpose of calculating treatment emergence, onset time, and duration, the following date imputation rules will be used. Dates will be presented as is in the listings.

- Start Date
 - If start date is completely missing, it will be assumed that the AE started on the treatment date.
 - If the start date is missing the day, the first of the month will be used (i.e. UNK-JAN-2019 becomes 01-JAN-2019), provided the imputed date is on or after the subject's treatment date; otherwise, the day of treatment will be used.
 - If the start date is missing the month, the month of 'June' will be used (i.e. 01-UNK-2019 becomes 01-JUN-2019), provided the imputed date is on or after the subject's treatment date; otherwise, the subsequent month after treatment will be used.
 - If the start date is missing the year, the year of treatment will be used (i.e. 01-JAN-UNK becomes 01-JAN-2019), provided the imputed date is on or after the subject's treatment date; otherwise, the subsequent year after treatment will be used.
- End Date
 - If end date is completely missing, it will be assumed that the AE is still ongoing and will not be imputed.
 - If the end date is missing the day, the last of the month will be used (i.e. UNK-JAN-2019 becomes 31-JAN-2019)
 - If the end date is missing the month, the subsequent month after the start date will be used.
 - If the end date is missing the year, the year of treatment will be used (i.e. 01-JAN-UNK becomes 01-JAN-2019), provided the imputed date is after the start date; otherwise, the subsequent year after start date will be used.

2.5.2.1 Subgroup analysis

To evaluate the consistency of the AE data, subgroup analyses will be performed. All TEAEs related to study product or injection procedure by SOC, PT, and maximum intensity will be repeated by the following subgroups. The same methods specified above ([Section 2.5.2](#)) will be followed

- Age (less than 65 years old, 65+ years old)
- Gender (Male, Female)
- Prior use of botulinum toxin (Naive, Non-Naive)
- Race (White, Black, Other)
- Fitzpatrick skin type (I-III, IV-VI)
- Site

2.5.2.2 Assessment of local/remote toxin spread and hypersensitivity

Any potential or suspected toxin spread or toxin hypersensitivity events will be evaluated separately. The same methods specified in Section 2.5.2 will be followed. Suspected toxin spread events and suspected hypersensitivity events will be summarized in separate tables. The investigator will conduct the investigation and evaluate if an AE is also a suspected toxin spread or hypersensitivity event; however, Appendix 7 in the CSP lists AEs potentially suggestive of spread of toxin.

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

2.5.3 Laboratory assessments

The laboratory data (hematology and clinical chemistry) at Baseline Day 0 prior to treatment and Month 6, and the changes from baseline will be summarized by descriptive statistics. All clinically significant out-of-range laboratory values for blood samples collected at baseline will be recorded in the subject's medical history and all clinically significant out of range laboratory values for blood samples collected after baseline are to be reported as an AE if this abnormality was not present at the baseline visit or is assessed as having worsened since the baseline visit.

Throughout the study, it is possible that certain laboratory parameter results are below the limit of quantification (BLQ). Any BLQ laboratory values will be summarized by the imputed value of half the limit of quantification for that parameter.

All laboratory data will be presented in data listings as collected, without any imputations for BLQ values.

2.5.4 Neutralizing antibody testing

Sampling for antibody testing will be conducted at baseline Day 0, Month 1, and Month 6. For the antibody testing results, due to the timing and availability of the data, results will be presented in a separate report.

2.5.5 Physical examinations and vital signs

The number and percentage of subjects with normal/abnormal results in physical examination will be presented by visit and treatment. A shift table will be created to present any change from baseline in normal/abnormal results in physical examination across the study visits for each treatment group.

Vital signs at baseline, Day 7, Day 14, Month 1, and Month 6, and the changes from baseline will be summarized by treatment and visit using descriptive statistics.

2.5.6 ECG

The aggregated value of each ECG measurement (described in [Section 1.5.6](#)) at baseline, Month 1, Month 6, and the changes from baseline will be summarized descriptively by treatment group at each visit. In addition, a shift table will be created to show any change from baseline to Month 6 in the overall ECG assessment.

QTcF and QTcB interval prolongation will be presented separately as well. The number and percentage of subjects with a QTcF and/or QTcB interval of >450 msec, >480 msec, and >500 msec will be summarized by treatment and visit, along with the number and percentage of subjects with a change from baseline in QTcF and/or QTcB interval of 30 - < 60 msec and ≥60 msec.

2.5.7 Urine pregnancy test

A data listing will be provided to summarize the results of the urine pregnancy tests. All pregnancy SAEs will be flagged within the data listing.

2.6 Interim Analysis

Not applicable. An interim analysis is not planned for this study.

2.7 Determination of Sample Size

The sample size is determined by the number of subjects exposed to QM1114-DP in the LCL, and amount of long-term safety data. Further, due to the public health emergency related to the COVID-19 pandemic during 2020, steps have been taken to ensure patient and practitioner safety in alignment with FDA Guidance dated May 11, 2020 (Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency). Most notably, in partnership with clinical sites and the IRB, optional remote assessment procedures for efficacy and safety endpoints have been implemented to ensure safety and respect localized and elective restrictions. However, the number of subjects in the mITT population used in the assessment of the primary efficacy endpoint should still satisfy the sample size requirements for the primary efficacy analysis.

CCI

2.7.3 Sample size calculation

The study is planned to include approximately 300 subjects, of whom 225 will be treated with QM1114-DP and 75 subjects will receive placebo. CCI


CCI

2.8 Changes in Analysis Planned in the Protocol

The table below outlines all rationale and changes in the analyses specified in the SAP that differ from the analyses specified in the protocol.

Table 3 Changes in Analysis Planned in the Protocol

CSP Section	SAP section	Description/Rationale of Change
9.1.2.3 Per-protocol (PP) Efficacy Population	2.4.3.1 Sensitivity Analysis	A sensitivity analysis of the primary efficacy endpoint will be performed based on the PP population regardless of meeting the criteria for PP population containing less than 90% of subjects in the mITT population, as was specified in the protocol.


	<small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL	<small>Doc id</small> MA-43263
--	--	--

3 Reference List

Effective date: 2021-02-05 13:17

Effective

Version: 1.0

	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	---	---


Effective date: 2021-02-05 13:17


Effective

Version: 1.0

4 Appendix A LCL-ILA Scales

CCI



	Title 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

Dynamic

0 None

Smooth skin, no lines that are immediately noticeable.

1 Mild

Lines that are noticeable but not pronounced.


2 Moderate


Lines that are immediately noticeable and pronounced.

3 Severe

Lines that are immediately noticeable and extremely pronounced.

CCI



	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	---	---


Effective date: 2021-02-05 13:17


Effective

Version: 1.0

5 Appendix B LCL-SLA Scales

CCI



	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	---	---

Dynamic

Level 0

Smooth skin, no lines that are immediately noticeable.

Level 1

Lines that are noticeable but not pronounced.


Level 2

Lines that are immediately noticeable and pronounced.

Level 3

Lines that are immediately noticeable and extremely pronounced.


CCI



Effective

Effective date: 2021-02-05 13:17


Version: 1.0


	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	---	---

Effective date: 2021-02-05 13:17

Effective

Version: 1.0




	<div>Title</div> 43QML901 Statistical Analysis Plan US - QM1114-DP - LCL	<div>Doc id</div> MA-43263
--	---	-----------------------------------

Effective date: 2021-02-05 13:17

Effective


Version: 1.0




Effective date: 2021-02-05 13:17


Effective

Version: 1.0

	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	--	--

CCI




	<p><small>Title</small> 43QMI901 Statistical Analysis Plan US - QMI114-DP - LCL</p>	<p><small>Doc id</small> MA-43263</p>
--	---	---

Effective date: 2021-02-05 13:17

Effective

Version: 1.0



	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

9 Appendix F Schedule of Assessments

Definition 1 month = 4 weeks/28 days All visit windows are calculated from Baseline/Day 0	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10
	Screening ¹	Baseline/Day 0 ¹ (within 2 weeks after screening)	Day 7 (±1 day)	Day 14 (±3 days)	Month 1 (±5 days)	Month 2 (±5 days)	Month 3 (±5 days)	Month 4 (±5 days)	Month 5 (±5 days)	Month 6/ET ² (±5 days)
Informed Consent	X									
Demographic Data ³ including, Fitzpatrick skin type, medical history & concurrent diseases, previous facial treatments/procedures (toxin naïve/non-toxin naïve)	X									
Inclusion /Exclusion Criteria	X	X ⁴								
Concomitant Therapies/ Procedures	X	X ⁵	X	X	X	X	X	X	X	X
Adverse Events	X	X ⁵	X	X	X	X	X	X	X	X
Urine Pregnancy Test ⁶	X	X ⁴								X
Vital Signs (blood pressure, heart rate, and respiratory rate) ⁷		X ⁵	X	X	X					X
ECG		X ⁴			X					X
Blood sample clinical chemistry and hematology		X ⁴								X
Blood sample for serum antibody testing		X ⁴			X					X
ILA of LCL Severity	X	X ⁴	X	X	X	X	X	X	X	X
CCI										
Photography		X ⁴	X	X	X	X	X	X	X	X
Randomization		X ⁴								
Treatment		X ⁹								
CCI										
Subject assessments										
SLA of LCL Severity ¹⁰	X	X ⁴	X	X	X	X	X	X	X	X
CCI										

1. Screening and baseline visits may be on the same day. If completed on the same day, only perform study assessments once (i.e., PE, UPT, SLA, ILA, AE, concomitant therapies/procedures, inclusion/exclusion review)

2. If the subject withdraws before the final visit the assessments at Month 6/ET should be completed, if possible.

3. Includes date of birth, gender, race, ethnicity, height, and weight.

4. To be performed before treatment.

5. To be performed before treatment and post-treatment.


6. Females of childbearing potential.

7. Vital signs are taken seated after 10 minutes rest. Vital signs are taken prior to any blood draw (excluding post-treatment measurements on Day 0).

CCI

9. Following treatment administration, subjects will be monitored at the study center for 30 minutes.


10. Subjects will make their Lateral Canthal Line assessments independently of the Investigator's assessment.


	Title	Doc id
	43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	MA-43263



PPD



Statistical Analysis Plan Approval Form

Client:	Galderma
Identifier (e.g., Protocol Name and Number, ISS, ISE, SCS, or CSE):	43QM1901 LCL
Version (Protocol Only):	<input type="checkbox"/> Original, Date: _____ <input checked="" type="checkbox"/> Amendment, Number 4.0; Date: 10JUN2020
Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines (READY - 2)
Statistical Analysis Plan Version:	<input checked="" type="checkbox"/> Original, Date: 29OCT2020 <input type="checkbox"/> Amendment, Number _____; Date: _____

AC Statistical Analysis Plan Author:	
PPD, Sr. Biostatistician	
Printed Name & Title	
<i>Handwritten Signature</i> OR	<i>Electronic Signature</i>
Signature: _____ Date: _____ (dd/mm/yyyy)	PPD  DocuSign

AC Statistical Analysis Plan Reviewer:	
PPD, Sr. Biostatistician	
Printed Name & Title	
<i>Handwritten Signature</i> OR	<i>Electronic Signature</i>
Signature: _____ Date: _____ (dd/mm/yyyy)	PPD  DocuSign

First Client Statistical Analysis Plan Approval:	
PPD, Sr. Biostatistician	
Printed Name & Title	
Signature: PPD 	Date: PPD  (dd/mm/yyyy)

Second Client Statistical Analysis Plan Approval <input type="checkbox"/> Not Applicable	
PPD, Biostatistical Consultant	
Printed Name & Title	
Signature: PPD 	Date: PPD  (dd/mm/yyyy)

	Title 43QM1901 Statistical Analysis Plan US - QM1114-DP - LCL	Doc id MA-43263
--	--	----------------------------------

SIGNATURES PAGE

Date	Signed by
2020-11-27 15:59	PPD
Justification	Approved by Technical Expert
2020-11-30 08:15	PPD
Justification	Approved by Owner
2021-02-05 13:17	PPD
Justification	Approved by

Effective date: 2021-02-05 13:17

Effective

Version: 1.0